Form 4: Acrivon Therapeutics Executive Erick Gamelin Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports disposing of 403 shares to cover tax obligations related to vesting restricted stock units.
Summary
- On May 14, 2025, Erick Gamelin, the Chief Development Officer of Acrivon Therapeutics, Inc. (ACRV), disposed of 403 shares of common stock.
- The disposal was executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The price per share was $1.14.
- Following the transaction, Gamelin directly owns 16,089 shares of Acrivon Therapeutics.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock disposal for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of stock disposal transaction |
| 05/16/2025 | Date of signature for the report |
Keywords
Form 4, Acrivon Therapeutics, Erick Gamelin, Stock Disposal, Tax Withholding, ACRV, Chief Development Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.